This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

NSCLC additional analyses and Real-world evidence

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: October 2018